title: [Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
abstract: Secondary hyperparathyroidism and vascular calcification are major clinical states in CKD-MBD (chronic kidney disease-mineral and bone disorder) . Recently fibroblast growth factor 23-klotho axis has been shown to be implicated in the pathogenesis of secondary hyperparathyroidism. Vascular calcification has been identified to be a highly regulated process. Novel therapeutic agents for CKD-MBD have been developed. The guidelines of CKD-MBD have been announced from many countries including Japan from the point of view of patient's survival, and it is expected that the development of practice for CKD-MBD will contribute to better survival.
authors: Department of Nephrology, Showa University School of Medicine, Japan.
authors: Masahide
authors: M
authors: Mizobuchi
authors: Ai
authors: A
authors: Nakazawa
authors: Tadao
authors: T
authors: Akizawa
mesh_terms: D001851:Bone Diseases, Metabolic / Q000150:complications / Q000188:drug therapy*; D002908:Chronic Disease; D000069449:Cinacalcet; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000502:physiology; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000235:genetics; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D000090265:Klotho Proteins; D007811:Lanthanum / Q000627:therapeutic use*; D008565:Membrane Proteins / Q000502:physiology; D009281:Naphthalenes / Q000627:therapeutic use*; D061205:Vascular Calcification / Q000209:etiology / Q000235:genetics; D014807:Vitamin D / Q000627:therapeutic use*
chemical_list: C418622:Klb protein, mouse; D008565:Membrane Proteins; D009281:Naphthalenes; D014807:Vitamin D; C119467:lanthanum carbonate; D005346:Fibroblast Growth Factors; D007811:Lanthanum; D000089703:Fibroblast Growth Factor-23; D000090265:Klotho Proteins; D000069449:Cinacalcet